TABLE II.
Plaque phenotype changes (frame-level).
Baseline | Follow-up | ||||||
---|---|---|---|---|---|---|---|
TCFA | ThCFA | FcP | FP | PIT | NL | ||
TCFA | 408 (6%) | 55 | 148 | 13 | 109 | 71 | 12 |
ThCFA | 1068 (17%) | 36 | 390 | 59 | 205 | 277 | 101 |
FcP | 140 (2%) | 2 | 45 | 32 | 12 | 35 | 14 |
FP | 826 (13%) | 4 | 108 | 19 | 314 | 279 | 102 |
PIT | 2005 (32%) | 17 | 128 | 20 | 719 | 881 | 240 |
NL | 1894 (30%) | 10 | 51 | 18 | 86 | 196 | 1533 |
Total | 6341 | 124 (2%) | 870 (14%) | 161 (3%) | 1445 (23%) | 1739 (27%) | 2002 (32%) |
Values are n or n (%). Plaque phenotypes were automatically labeled as given in [34].
TCFA: virtual histology-derived thin-cap fibroatheroma; ThCFA: thick-cap fibroatheroma; FcP: fibrocalcific plaque; FP: fibrous plaque; PIT: pathological intimal thickening; NL: No lesion.